The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.632%)
Open: 19.25
High: 19.25
Low: 18.75
Prev. Close: 19.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics Real-Status deal

1 Mar 2011 07:00

RNS Number : 0271C
Angle PLC
01 March 2011
 



 

 

For immediate release

1 March 2011

 

ANGLE plc ("the Company")

 

Geomerics Real-Status deal

 

ANGLE plc, which focuses on the commercialisation of technology and the development of technology-based industry, is pleased to announce that its 35% owned portfolio company Geomerics Limited, which specialises in computer games middleware, has secured a 12% equity stake in Real-Status Limited worth £0.45 million in exchange for the right to use certain of Geomerics' non-core intellectual property.

 

Real-Status targets the $1.3 billion sector of IT dashboard and analysis software. Real-Status is due to launch its first product, which is currently in customer trials, in the second quarter of 2011. Real-Status has today announced completion of a funding round raising £1.2 million to commercialise this product and further develop its business.

 

Real-Status' product creates real-time 3D visualisation of computer networks and overlays performance and business metrics, enabling IT managers and Chief Information Officers to see a virtual model of their entire ICT infrastructure. This facilitates the rapid identification of issues and enables users to organise their network and IT systems to give optimal performance and utilisation. For more information, visit www.real-status.com.

 

The non-core intellectual property licensed to Real-Status is separate from and not dependent on Geomerics' core intellectual property. It was developed separately under a joint project with Intergence, part-funded by the UK Government Technology Strategy Board. Geomerics received grant income of £0.22 million in relation to this development work.

 

The value of the equity holding in Real-Status is based on the value attributed to Real-Status in its third party funding round. The deal generates a profit for Geomerics of £0.45 million. If Real-Status fulfils its potential in the emerging ICT visualisation market, Geomerics' equity holding in Real-Status has the potential to rise substantially in value.

 

 

Royce Murphy, CEO of Real-Status commented:

"We are delighted to have closed the funding round and intellectual property agreement with Geomerics. IT dashboard and analysis software is already a $1.3 billion market, and Real-Status' technology promises break-through products that will display virtual and physical infrastructure together in a scalable way. 2011 is set to be a very successful year for both Real-Status and our, soon to be announced, ICT modelling and visualisation product."

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"The Real-Status deal provides Geomerics' shareholders with the potential for additional return without distraction of resources from the core business. Geomerics' business continues to strengthen. Sales of Enlighten, Geomerics' computer games lighting solution, are developing and its corporate partnership with one of the world's leading technology companies is progressing well with the first milestone successfully completed."

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Stewart Wallace

 

0207 523 8350

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

 

 

Notes to Editors

 

ANGLE plc

 

Founded in 1994, ANGLE focuses on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

 

ANGLE's specialist Management services business provides support on a fee-for-service basis to major clients around the world involved in incubation, IP commercialisation, SME innovation and growth and the operation of science & technology parks.

 

ANGLE also owns a portfolio of company holdings with high growth potential in the medical and technology sectors. These have been developed whilst subsidiaries of ANGLE using its proprietary Progeny® process. ANGLE seeks to retain a substantial shareholding in these companies with a view to ongoing returns from dividend, milestone, royalty and capital returns.

 

ANGLE's technology commercialisation skills are of increasing relevance as global economies focus on regeneration, innovation and value added components to their industries. ANGLE's technology skills in IT and software, medical and life sciences, cleantech and renewable energies are directly relevant to major growth markets of the future and are marketed as specialised Management services.

 

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDVLFLFLFFBBE
Date   Source Headline
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSIssue of Equity
30th Sep 20225:30 pmRNSHolding(s) in Company
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.